Arixtra is indicated for the prophylaxis of deep vein thrombosis.
Mylan will pay $225 million to acquire the rights for commercialization, marketing and intellectual property. Another $75 million is contingent upon satisfaction of certain conditions.
More articles on acquisitions:
3 recent hospital transactions and partnerships
J&J seeks buyer for medical device business
Covidien acquires medical device firm Sapheon
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
